Abstract: The standard treatment for autoimmune hepatitis (AIH) is predniso(lo)ne for remission induction, tapered and followed by azathioprine, which effectively controls the disease in the majority of patients. However, some patients prove to be unresponsive or non-tolerant and require alternative immunosuppressive regimens for disease control. We aimed to investigate whether these AIH patients who experience failure of standard treatment have a genomic basis for their problem in the form of pharmacogenetic variants. Fifty-six consecutive patients with AIH [41 female and 15 male; median age 42 years (12-76)] were retrospectively stratified according to being responders to standard therapy (n = 33) or patients with failure of standard therapy (n = 23). Their blood DNA was exome-captured and sequenced. Genomic variants were filtered and compared between the groups using Ingenuity Variant Analysis (3
Autoimmune hepatitis (AIH) is a chronic, progressive, inflammatory liver disease that without treatment and even with long-term immunosuppressive therapy can lead to cirrhosis and premature death [1, 2] . The standard treatment strategies are based on data generated 40 years ago [1, 3, 4] and consist of initial high-dose prednisolone, followed by a tapered dose in combination with azathioprine [5, 6] . This regimen is highly effective in the majority of patients and has well-documented beneficial effects on symptoms, laboratory tests, histology and immediate and long-term survival [1, 3, 4] . The early response is so consistent that it is even included as part of the diagnostic criteria [6, 7] . However, a significant fraction of the patients do not respond to standard therapy, which represents a major clinical challenge. Response rates to standard treatment reached 65-80% in early trials but were presumably deflated by unidentified cases of viral hepatitis [8] ; still, however, approximately 10-15% of the patients are insufficient responders and another 10-15% intolerant to the standard therapy [5] . They comprise a group of patients at high risk of disease progression and development of liver failure or liver cirrhosis with its associated complications and possible requirement for liver transplantation due to end-stage liver disease [9] . These patients are in need of more aggressive immune-modulating treatment, and valuable time may be lost awaiting the absent response to standard treatment.
Genetic factors affect the occurrence and clinical expression of AIH [10] . The disease being characterized by chronic inflammation of the liver together with hypergammaglobulinaemia and production of autoantibodies [5] implies the search for such genetic factors to be focused on the immune system. This has revealed that genes associated with an increased disease risk include specific alleles of the major histocompatibility complex and polymorphisms in the human leucocyte antigen (HLA) DRB1-gene [11, 12] . Genetic factors may also affect treatment response. In AIH, this has been shown for the HLA-DRB1*0301 allele [13, 14] . With regard to genes related to the standard treatment of AIH, it is known that pharmacogenetic variants can be associated with an altered sensitivity to immunosuppressive treatment, including glucocorticoids [15] , but only few studies have ever reported this to affect the treatment response in diseases [16] [17] [18] . Moreover, drug intolerance can have a genetic basis, and approximately 10% of the population has reduced activity of the enzyme thiopurine S-methyltransferase (TPMT), which is involved in azathioprine metabolism [19, 20] , with an increased risk of side effects to azathioprine treatment [20] .
The aim of this study was to explore whether pharmacogenetic variants determine the treatment response in AIH. We screened blood exomes in a retrospective cohort study of AIH patients who were stratified according to response or failure of standard Author for correspondence: Peter Lykke Eriksen, Department of Hepatology & Gastroenterology, Aarhus University Hospital, 44 Noerrebrogade, DK-8000 Aarhus C, Denmark (e-mail ple@clin.au.dk).
treatment. Single-nucleotide variant (SNV) data were analysed using Ingenuity â Variant Analysis TM software and filtered to include predicted deleterious pharmacogenetic variants.
Materials and Methods
Fifty-six consecutive patients treated for non-overlap syndrome type-1 AIH (41 female and 15 male; median age at diagnosis 42 years (12-76)) were included in a retrospective cohort study at the Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark. The patients' medical histories, including treatment regimens and disease course, were accessed, and the cohort was then stratified according to treatment response as responders to standard therapy and patients with failure of standard therapy. Standard therapy [5] consisted of initial high-dose prednisolone (~1 mg/kg/day), followed by tapering of prednisolone to a maintenance dose of <10 mg/day alone or in combination with azathioprine (1-2 mg/kg/day). Thirty-three patients (59%) responded completely to this regimen with stable normalization of alanine aminotransferase (ALT) and immunoglobulin G (IgG) levels [5] . Twenty-three patients (41%) experienced failure of standard therapy, and other immunosuppressive regimens were applied (table 2). This group included both patients who had their treatment altered because of side effects to azathioprine and patients who did not respond to the standard regimen (in the literature referred to as patients with treatment failure and incomplete response [5] ). The latter group also comprised one patient who had to be liver-transplanted early in the disease course.
Written informed consent regarding participation in the study was obtained from all patients, and the study was approved by The Central Denmark Region Committee on Biomedical Research Ethics (journal no.: 1-10-72-89-12).
Diagnosis of AIH, biochemical analyses and HLA class-II alleles. In all patients, the diagnosis of AIH was established using the standard criteria of elevated liver transaminases, elevated IgG levels, positive smooth muscle cell (SMA) and antinuclear (ANA) antibodies and, in all patients, a liver biopsy demonstrating characteristic lesions. Viral and alcoholic aetiology was excluded as usual. A pre-and posttreatment initiation AIH score was calculated [7] .
Biochemical data were available from the time of diagnosis and during the course of the disease. The concentrations of ALT, alkaline phosphatase, total bilirubin, external coagulation factors (II, VII, X) and IgG were determined using accredited standard laboratory assays and methods. HLA-DRB1 genotype was determined using accredited laboratory PCR-based methods and was available for all patients except three responders.
Exome analysis. A genomic (g)DNA library was prepared for each patient from DNA extracted from whole blood using TruSeq DNA library preparation kits (Illumina, San Diego, California, U.S., following the gel-free protocol) followed by exome enrichment using SeqCap_EZ_Exome_v3_(Roche Nimblegen, Basel, Schweiz), all according to the manufacturer's manual. The size distribution of the gDNA libraries was estimated by on-chip electrophoresis (DNA 1000 DNA chip) of a 1-lL sample on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California, U.S.). The concentration of the libraries was estimated using the KAPA Library Quantification Kit (Kapa Biosystems, Wilmington, Massachusetts, U.S.). Exome targeting was performed on pools of up to 6 gDNA libraries using 1 lg of each gDNA library according to the manufacturer's recommendations.
Indexed libraries were paired-end sequenced (2 9 101 bp) on an Illumina HiSeq 2000 using TruSeq SBS Kit v3 chemistry (Illumina). On average, 157 million read pairs were sequenced per sample, yielding a median exome coverage of 67 reads (range 42-131).
Bioinformatics and statistics. Fastq files were prepared with CASAVA (v1.8.2) (Illumina, San Diego, California, U.S.) and qualitychecked using fastQC and fastqScreen (http://www.bioinformatics.bab raham.ac.uk/projects). Adapter sequences were trimmed from the 3 0 ends of reads using AdapterRemoval (v1.5) [21] . The paired-end sequences were mapped to the hg19 reference genome using bwa mem (0.7.5a-r405) [22] . PCR and optical duplicates were removed from each library (Picard package (v1.96; http://broadinstitute.github. io/picard), and the final bam file was realigned around indels (gatk v3.1.1 IndelRealigner [23] ) and its base quality scores were adjusted in regions with systematic technical errors from the sequencing machine (gatk BaseRecalibrator) using data from dbSNP, 1000G, Mills_and_1000G_gold_standard indels. Basic alignment statistics were calculated using picard CalculateHsMetrics and CollectInsertSizeMetrics. SNPs were called using a two-step approach, first producing a genomic VCF file for all samples and finally calling a combined variant file taking all samples and external data from dbsnp_138 hapmap_3.3 1000G_omni2.5 1000G_phase1 .snps.high_confidence and Mills_and_1000G_gold_standard indels into account.
Genomic variants were analysed using Ingenuity â Variant Analysis TM software version 3.1.20150407 (http://www.ingenuity.com) by comparing the group of responders to standard therapy and the group of patients with failure of standard therapy. After filtering, this software identifies variants that are enriched in one group compared to the other. Via Ingenuity â Knowledge Base, the variants are put into biological context by assigning them to pathways. The significance level of the variant enrichment in pathways compared to the expected frequency of variants is calculated using a right-tailed Fisher's Exact Test.
The variant filtering algorithm:
• A variant was excluded if it was observed to have an allele frequency ≥15.0% of the genomes in the '1000 Genomes Project', ≥15.0% of the 'public Complete Genomics genomes' or ≥15.0% of the 'National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project' (ESP) exomes (All). This filtering step excluded variants occurring so frequently in the background population that they are unlikely to be of importance.
• A variant was kept for further filtering if it was described to be associated with a phenotype as: pathogenic, possibly pathogenic, unknown significance or disease-associated according to 'human gene mutation data' (HGMD); if it had an established gain of function in the literature; if it was a gene fusion; if it had inferred activating mutations by the Ingenuity â software (QIAGEN, Venlo, Netherlands); if it had predicted gain of function based on the 'bidirectional Sorting Intolerant from Tolerant' (BSIFT) algorithm; if it was detectable as a microRNA binding site; if it was a Frameshift, inframe indel, or stop codon change; if it was a missense variant; if it was a disrupted splice site up to 2.0 bases into the intron; if it was deleterious to a microRNA; if it was a structural variant; if it was found in a promoter binding site; or if it was found in an enhancer. This filtering step insured that the functionally important variants were included.
• A variant was kept for further filtering if it was associated with a gene-based case-control burden test p-value ≤ 0.05 or if it, based on a variant-level basic allelic model, had an odds ratio in patients with failure of standard therapy over responders to standard therapy ≥1.5. This filtering step identified and included statistically significant occurrence of variants.
• Finally, a variant was kept as a result if it was reported to be associated with response, metabolism or toxicity, established target(s), or other drug binding of drug(s). This step ensured that we included only variants of pharmacogenetic importance.
Furthermore, all the patients were investigated for the most frequent non-functional TPMT gene variants (name, SNP) [20] : TPMT*2 (rs1800462), TPMT*3A (rs1800460 and rs1142345), TPMT*3B (rs1800460) and TPMT*3C (rs1142345).
The data were compared statistically using chi-square test and Fisher's exact test for ordinal data. Student's t-test for parametric data and the Mann-Whitney U-test for nonparametric data were used for comparison among groups. A p-value < 5% was regarded as being significant in a two-sided test. The data are presented as the median and range.
Accession of data. All data underlying the findings described in the manuscript are fully available on a group level without restriction. Access to the sequence data can be obtained following a request to the MOMA Data Access Committee.
Role of the funding source. The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Cohort characteristics. Table 1 shows the characteristics of the AIH patients at diagnosis. Most patients were female, with no difference in the gender distribution between the groups. There was no difference in age and no difference in time from AIH diagnosis to inclusion. At diagnosis, there was no difference in laboratory values, including IgG, except for ALT, which was higher in the group responding to standard therapy (median 820 (90-2128) versus 405 (40-2700), p = 0.04). Thirty-four patients had definite AIH at diagnosis according to their post-treatment score (score >17): 16 responders and 18 patients with failure of standard therapy. Except for three responding patients, where biochemical data were insufficient for score calculation, the remaining patients had probable AIH (score = 12-17): 14 responders and five patients with failure of standard therapy. fig. 1 ). When the software assigned biological context to these variants, the single most affected pathway and the only pathway related to pharmacogenetics were the glucocorticoid receptor signalling pathway (p = 9.22 9 10 À33 ).
Within this pathway, 134 variants in 64 genes were identified, equi-distributed, among the patients with failure of standard therapy ( fig. 2 ; Appendix S1). A majority of these (90%) were SNVs, while~5% were insertions and deletions.
Thiopurine S-methyltransferase mutations and HLA genotypes. The presence of TPMT mutations was not related to treatment failure. TPMT*3A was the only TPMT mutation identified and was found in six patients (three responders to standard therapy and three patients with failure of standard therapy). Eighty-three per cent of the patients in our cohort had the genotypes HLA-DRB1 *03 or *04, which are reported to be associated with the diagnosis, severity and treatment response of AIH [10, 14] . However, we found no difference in the frequency of these genotypes between the two AIH groups.
Discussion
The key finding of the present study is that genetic variants with predicted deleterious effects in the glucocorticoid receptor signalling pathway were highly enriched in the AIH patients with failure of standard therapy.
Our study comprised a group of well-characterized patients with biopsy-proven AIH. The characteristics of the 56 patients were largely in accordance with data from a recent large national population-based cohort study [2] of 1721 AIH Fig. 2 . Glucocorticoid receptor signalling pathway. Red asterisk (*), protein encoded by genes enriched in variants among the AIH patients with failure of standard therapy. SERPINA6, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6; NR3C1, nuclear receptor subfamily 3, group C, member 1; FKBP4, FK506 binding protein 4, 59 kDa; HSPCA, heat-shock protein alpha (cytosolic), class A; HSPA4, heat-shock 70-kDa protein 4; ST13, suppression of tumorigenicity 13 (Hsp70-interacting protein); NCOA3, nuclear receptor coactivator 3; CBP, cAMP response element-binding protein (CREB) binding protein; hSWI/SNF, SWI/SNF-related, matrix associated, actin-dependent regulator of chromatin; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; AIH, autoimmune hepatitis; TFIIB, transcription factor II B; POLII, polymerase II; TAFs, TBP-associated factors; GRE, glucocorticoid response elements; TATA, TATA box; TBP, TATA-binding protein. N.B.: Variations were found in genes coding for different heat-shock proteins not shown in this figure -see Appendix S1. Based on: Whirl-Carrillo et al. [24] . patients, including the incidence of cirrhosis at diagnosis (35% versus 28%). The stratification of patients into the two groups of response to standard treatment and patients with failure of standard therapy was based on established international criteria and a complete medical history containing a description of treatment regimens and disease course, including continuous measurements of ALT and IgG, after the time of diagnosis [6] .
The failure of standard therapy was not predicted by disease severity or the presence of cirrhosis at diagnosis. If anything, judged on their higher ALT, the responders to standard therapy seemed to have more active disease at diagnosis. Our patients were included from a single specialized department with referral functions that might favour the inclusion of more severe cases. Even though the fraction of 41% of our patients who failed on standard therapy might seem high, it is, however, comparable to the combined proportion of treatment failure, incomplete response and drug toxicity reported elsewhere [5] . A risk of genetic population bias seems unlikely, as the patients were non-related Danish Caucasians from a genetic homogeneous patient pool of 1.2 million people [25] .
AIH is a complex, polygenic disorder. Genetic determinants such as the presence of the HLA-DRB1*0301 allele have already been reported to predict a poor treatment response [13] . Without pinpointing additional specific outcome-predicting genetic variants, the pathway-based analysis that we present may provide new insight into pre-defined factors that likely add to the failure of standard treatment. The findings may suggest that a gauge for glucocorticoid receptor sensitivity could constitute a means of risk stratification at treatment initiation. Such a method does not yet exist, and the cortisol suppression by dexamethasone suppression test is only used to test total suppression and is not likely to identify patients who fail to respond to glucocorticoid therapy.
Although associated with glucocorticoid action, not all genes of the glucocorticoid receptor pathway are identified as direct transmitters of classical glucocorticoid effects. Glucocorticoids exert their function through both gene transcription and direct cellular effects, and glucocorticoid signalling is coupled to numerous pathways [26] . Likewise, the enrichment of genetic variants found in our patients with failure of standard therapy was distributed throughout the genome.
At a single variant level, we found variants predicted to increase and variants predicted to impair glucocorticoid signalling. One example is the N363S polymorphism in the glucocorticoid receptor gene, NR3C1. Several polymorphisms in the glucocorticoid receptor are functionally relevant, including the N363S polymorphism [27] . This polymorphism was found in two patients with treatment failure and none of the responders. Notably, this variant shows an increased activity in vitro and is associated with greater cortisol suppression by dexamethasone in humans [28, 29] . It therefore remains undetermined whether glucocorticoid signalling in the patients with failure of standard therapy was impaired in every respect. However, our data taken together indicate that the phenotypic capacity to react to glucocorticoid treatment is inherently different in the patients with failure of standard therapy.
An obvious limitation of the present study is the small number of subjects analysed. The total of 134 variants was spread throughout the genome, and no single detrimental genetic variant could be identified, but it remains uncertain if even a much larger patient sample would make this possible. In any event, the impact of a single variant on the complex outcome of treatment response is probably low, whereas an additive effect of multiple variants, such as we describe, is more likely to be of functional significance. Filtering for pharmacogenetic effects and its resulting consistent excess of variants related to glucocorticoid receptor signalling in the patients with failure of standard treatment may offer one pathophysiological explanation for their problems in attaining disease control. Larger replication cohorts are warranted to further elucidate this connection. Also, a larger cohort would make separate analysis of standard treatment non-responders and intolerants possible. Moreover, other types of sequencing including whole genome analysis, including introns, could reveal additional genetic differences.
Azathioprine intolerance was not related to the presence of TPMT mutations, and hence, it was probably ascribable to high drug exposure. Similar observations have been done in systemic lupus erythematosus and inflammatory bowel diseases [30, 31] .
In conclusion, we found marked enrichment of variants in genes related to glucocorticoid receptor signalling among AIH patients with failure of the standard treatment regimen of prednisolone and azathioprine to achieve disease control. These pre-defined pharmacogenetic factors may offer part of the pathophysiological explanation for difficult-to-treat AIH cases and should be further explored. One perspective is the potential to immediately identify patients who need non-standard immune therapy to obtain rapid disease control in the hope of preventing some of the dangerous clinical courses of AIH.
